Target intelligence / Profile preview

Autophagy regulation pathway

Molecular classification
Other (cellular signaling pathway)
01

Overview

Autophagy regulation pathways comprise the network of signaling and molecular events that control the induction, progression, and termination of autophagy—the conserved cellular process where cytoplasmic constituents are sequestered in autophagosomes and degraded following lysosomal fusion. The most canonical regulators include mTOR (negative regulator) and AMPK (positive regulator), which signal through the ULK1 complex to control autophagy initiation. Downstream, proteins such as Beclin-1 and various ATGs coordinate autophagosome nucleation, elongation, maturation, and substrate selectivity. These pathways integrate environmental cues (e.g., nutrient levels, stress) and are pivotal for cell survival, quality control, and disease adaptation, linking autophagy to a wide spectrum of physiological and pathological states. In summary, "Autophagy regulation pathways" is not a discrete molecular drug target/receptor, but an umbrella term for a collection of signaling processes that coordinate autophagy and are modulated pharmacologically via distinct upstream nodes.

Other names
Autophagy pathwaysAutophagy signaling pathwaysAutophagy regulatory networkmTOR pathway (when referring to its autophagy-regulatory role)AMPK pathway (context-dependent)
02

Mechanism of action

mTOR inhibition (de-represses autophagy initiation via ULK1 complex) AMPK activation (stimulates autophagy through ULK1 activation and mTOR inhibition) Lysosomal inhibition (blocks the completion phase of autophagy, causing autophagosome accumulation)

03

Biological functions

Regulation of autophagyCellular homeostasisResponse to metabolic stressOrganelle and protein quality controlCell survival during starvationAdaptation to environmental changes
04

Disease associations

CancerNeurodegenerative diseaseCardiovascular diseaseInflammationInfectionOther (due to its broad role in cell homeostasis and stress adaptation)
05

Safety considerations

Excess autophagy can contribute to cell death and tissue atrophyBlockade of autophagy may cause accumulation of toxic aggregates/organellesTargeting autophagy may threaten normal homeostasis, especially in metabolically active tissues
06

Interacting drugs

Rapamycin (targets mTOR, a major autophagy regulator)

3 more in the full profile.

07

Biomarkers

LC3-II/LC3B (marker for autophagosome formation)p62/SQSTM1 (selective substrate, accumulates when autophagy impaired)Beclin-1 (initiator protein, often monitored in autophagy studies)

Beyond the preview

Go deeper on Autophagy regulation pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autophagy regulation pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call